The GST Council has cleared a notable change in the indirect tax framework for the pharmaceutical industry, permitting companies to claim input tax credit, or ITC, on free samples and on goods that are destroyed after expiry, beginning from the next fiscal year. The reform, which will take effect from FY28, marks a meaningful shift in how the tax system treats products that never generate revenue but are nonetheless integral to drug marketing, physician outreach and inventory control.
Tax Relief Shift
Until now, pharmaceutical companies have faced a structural tax disadvantage on free samples and expired stock, because the GST regime did not fully recognise the commercial necessity of such outflows. Free samples are widely used in the sector to introduce new medicines, support physician familiarity and expand market penetration, while expiry-related destruction is an unavoidable feature of a heavily regulated industry with strict quality and shelf-life requirements. By allowing ITC in these cases, the Council has effectively acknowledged that these costs are part of the business process rather than discretionary wastage.
The decision is especially significant because it addresses a long-standing compliance and accounting pain point for drug makers. Under the earlier framework, firms often had to absorb the tax cost on inputs used to manufacture samples or on products that were later destroyed after expiry, even though those goods never resulted in taxable sales. That treatment created a mismatch between tax liability and commercial reality, particularly for companies with large product portfolios, extensive distribution networks and high levels of sample-based promotion.
Industry Cost Impact
For the pharmaceutical sector, the change could improve working capital efficiency and reduce the effective tax cost of doing business. The ability to claim ITC on free samples may lower the net burden on manufacturers that rely on product sampling as a core marketing tool. Likewise, allowing credit on expired and destroyed goods should reduce the tax penalty associated with inventory obsolescence, a risk that is especially acute in a sector where product life cycles, regulatory recalls and batch management are tightly monitored.
The reform may also have broader implications for pricing and compliance. While it is premature to quantify the exact savings, companies are likely to welcome the move as a rationalisation measure that brings GST closer to industry practice. It could also reduce disputes between taxpayers and tax authorities over whether credit should be denied on goods that are not ultimately sold. In a sector where margins can be sensitive to regulatory costs and distribution inefficiencies, even incremental relief can matter.
At the same time, the change will require careful implementation. Companies will need to maintain robust documentation to establish that samples were genuinely distributed without charge and that expired goods were properly destroyed in accordance with applicable rules. The tax administration, for its part, will likely expect clear audit trails to prevent misuse of the concession. As with any ITC-related relaxation, the practical value of the measure will depend on how precisely the rules are drafted and how consistently they are enforced.
Next Fiscal Framework
The timing of the reform is also important. By making the changes effective from the next fiscal year, the Council has given businesses a transition window to adjust systems, accounting processes and compliance protocols. That lead time should help companies incorporate the new treatment into budgeting and tax planning, while also allowing the government to refine the legal and procedural details needed for implementation.
More broadly, the decision reflects a continuing effort to fine-tune GST in response to sector-specific concerns. The pharmaceutical industry has often argued that tax rules should account for the unique nature of drug manufacturing, where samples, recalls, expiry losses and regulatory destruction are not peripheral events but routine operational realities. The Council's move suggests a willingness to address such distortions through targeted amendments rather than broad-based overhaul.
For policymakers, the reform balances revenue considerations against the need for a more neutral tax structure. For companies, it offers a measure of relief in an area that has long been viewed as an unnecessary tax drag. And for the wider economy, it is another sign that GST is gradually being adapted to reduce friction in sectors where compliance complexity has historically imposed hidden costs.
The pharmaceutical industry will now watch for the detailed notification and rule changes that will translate the Council's decision into operational practice. Those specifics will determine how far the relief extends, how claims will be verified and how quickly companies can begin reflecting the benefit in their tax positions from FY28 onward.